Tags : Initiation

Biosimilars

Samsung Bioepis Reports the Initiation of P-III Study for SB15

Shots: The P-III study will compare the efficacy, safety, PK, and immunogenicity between SB15 and Eylea in 446 patients with neovascular age-related macular degeneration The company has two ophthalmology biosimilar candidates in clinical development, SB11 (ranibizumab) and SB15 (aflibercept). On May 18, 2020, Samsung Bioepis reports 24-week interim results from a P-III study of SB11 […]Read More

COVID-19

Celltrion Anticipates the Initiation of its First-in-Human Clinical Studies Targeting

Shots: Celltrion has completed the selection of therapeutic Abs which showed potency for neutralizing the SARS-CoV-2 virus and anticipates cell-line development to initiate this week In collaboration with KCDC, Celltrion has identified 300 different types of Abs targeting SARS-CoV-2 antigen. Following the screening process, the company has captured 38 Abs, out of which 14 demonstrated […]Read More

COVID-19 Pharma

Novavax Accelerates the Initiation of Clinical Study for NVX-CoV2373 to

Shots: Novavax has identified a coronavirus vaccine candidate, NVX-CoV2373 utilizing its nanoparticle technology and will initiate a first-in-human trial in mid-May with its anticipated immunogenicity and safety results in July. Novavax will integrate its Matrix-M adjuvant with NVX-CoV2373 to improve the immune response stimulates high levels of neutralizing Ab The company plans to combine P-I/II […]Read More